Is OmniAb, Inc. (OABI) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for OmniAb, Inc. (OABI) using a discounted cash flow (DCF) model and long-term earnings assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is OABI a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether OABI trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

OABI

OmniAb, Inc.

$1.83

0.01

(0.27%)

Exchange:
Market Cap:	207.716M
Shares Outstanding:	114.821M

Overview

Earnings

Financials

Valuation

Chart

About The Company

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company’s discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

Click to read more…